C12Y 105/0103
Flavin reductase
Official title: Flavin reductase (1.5.1.30)
C12Y105/0103 (Flavin reductase) appears on 7 US grants and 10 published applications in this corpus.
Search patents in C12Y- Granted patents
- 7
- Published applications
- 10
- Assignees
- 9
- Inventors
- 42
- Latest grant
- 30 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 1 | 0 |
| 2008 | 1 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 2 | 1 |
| 2022 | 0 | 2 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Biosynthesis of eriodictyol30 Jun 2026US 12,668,804 B2Conagen Inc.
- Lux expression in cells and methods of use29 Jun 2021US 11,046,962 B2
- Biosynthesis of eriodictyol from engineered microbes13 Apr 2021US 10,975,403 B2Conagen Inc.
- Compounds9 Sep 2008US 7,422,749 B2Affinium Pharmaceuticals, Inc.
- Compounds13 Feb 2007US 7,176,299 B2Affinium Pharmaceuticals, Inc.
- Biological production of tryptophan-derived products12 Mar 2026US 2026/0071243 A1Board of Regents, The University of Texas System
- Color former based on fusion enzyme producing nitric oxide and use thereof23 Oct 2025US 2025/0325009 A1Hefei University of Technology
- Yeast cells and methods for production of tryptophan derivatives22 Dec 2022US 2022/0403428 A1Danmarks Tekniske Universitet
- Biosynthesis of eriodictyol13 Oct 2022US 2022/0325290 A1Conagen Inc.
- Lux expression in cells and methods of use15 Jul 2021US 2021/0214732 A1
Most cited
By later US patents